Pancreatic Cancer Research

ResearcherSalk Institute for Biological StudiesActive in the last 2 years

Ronald M. Evans

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9986-5965; OpenAlex author ID A5087519016; NIH RePORTER profile ID 1896344. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 4)
Trials
0
Grants
1
Labs led
1
Collaborators
96
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 4 papers, 1 grant

Papers 18

  1. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  2. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag232↗
  3. CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation Co-author DOI 10.64898/2026.04.08.717301↗
  4. CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.22.727290↗
  5. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  6. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  7. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Last author DOI 10.1038/s41467-023-40798-6↗
  8. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Last author DOI 10.1038/s41467-023-42178-6↗
  9. Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Co-author DOI 10.1016/j.medj.2021.12.008↗
  10. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  11. The autophagy initiating kinase ULK1 is required for pancreatic cancer cell growth and survival Co-author DOI 10.1101/2021.05.15.444304↗
  12. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Co-author DOI 10.1038/s41389-020-00285-9↗
  13. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  14. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Last author DOI 10.1073/pnas.1620164114↗
  15. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0256↗
  16. Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. Co-author DOI 10.1371/journal.pone.0189051↗
  17. Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-15-0204↗
  18. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Last author DOI 10.1016/j.cell.2014.08.007↗

Grants 1

  1. Core 3: Mouse Models Core (MM Core) P01CA265762↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dannielle D. Engle · 6 shared papers, 1 shared grant, 2014–2026 · strength 1.53
  2. Daniel D. Von Hoff · 10 shared papers, 2019–2026 · strength 1.42
  3. Tony R. Hunter · 5 shared papers, 1 shared grant, 2014–2026 · strength 1.22
  4. Geoffrey Myles Wahl · 4 shared papers, 1 shared grant, 2014–2026 · strength 0.94
  5. Erkut Hasan Borazanci · 6 shared papers, 2019–2026 · strength 0.89
  6. Haiyong Han · 6 shared papers, 2020–2025 · strength 0.87
  7. Reuben Shaw · 1 shared paper, 1 shared grant, 2021–2026 · strength 0.83
  8. Hervé Tiriac · 6 shared papers, 2014–2026 · strength 0.82
  9. Andrew M. Lowy · 6 shared papers, 2017–2026 · strength 0.74
  10. Herve Tiriac · 1 shared grant, 2026 · strength 0.71
  11. Gayle Jameson · 3 shared papers, 2025–2026 · strength 0.63
  12. Michael T. Barrett · 3 shared papers, 2023–2025 · strength 0.52
  13. Corina E. Antal · 5 shared papers, 2019–2023 · strength 0.49
  14. Jan C. Lumibao · 3 shared papers, 2021–2026 · strength 0.44
  15. Jasper Hsu · 2 shared papers, 2026 · strength 0.42
  16. Casie S. Kubota · 2 shared papers, 2026 · strength 0.42
  17. Satoshi Ogawa · 2 shared papers, 2026 · strength 0.42
  18. Hyemin Song · 2 shared papers, 2026 · strength 0.42
  19. Gaoyang Liang · 4 shared papers, 2019–2023 · strength 0.40
  20. Serina Ng · 3 shared papers, 2020–2023 · strength 0.35
  21. Carlos Roberto Becerra · 3 shared papers, 2019–2025 · strength 0.35
  22. Joshua D. Rabinowitz · 2 shared papers, 2022–2025 · strength 0.32
  23. David J. Propper · 2 shared papers, 2023–2025 · strength 0.32
  24. Yu Shi · 3 shared papers, 2019–2023 · strength 0.28
  25. Eric Andrew Collisson · 4 shared papers, 2014–2021 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.